Nancy Mills, MD
Medical Oncology · Sleepy Hollow, NYNPI 1992775795
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.0%), food and beverage and grants — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Athenex Pharmaceutical Division, LLC at 47.7% of the total. Reporting peaked in 2020 at $1,750 and has fallen 93.0% since, to $122 in 2025. That places this record below the midpoint for medical oncology clinicians in NY, where the typical reported total is $4,912.
Across 26 payments — averaging $203.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Athenex Pharmaceutical Division, LLC$3K
- AstraZeneca$921
- Daiichi Sankyo Inc.$675
- Amgen$258
- Merck$250
- Genentech USA, Inc.$150
- plus $512 from 5 others
Across 2 payments — averaging $10,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$20K
What the payments were for
- Speaking & faculty fees$2,80053%
- Grants$3507%
- Food & beverage$2,04139%
- Education$972%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Athenex Pharmaceutical Division, LLC | 6 | $2,522 |
| AstraZeneca | 6 | $921 |
| Daiichi Sankyo Inc. | 4 | $675 |
| Amgen | 2 | $258 |
| Merck | 2 | $250 |
| Genentech USA, Inc. | 1 | $150 |
| Genmab U.S., Inc. | 1 | $125 |
| Boehringer Ingelheim | 1 | $125 |
| Puma Biotechnology, Inc. | 1 | $125 |
| Novartis | 1 | $125 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,288 in reported general payments places this provider in the 50th percentile of 498 medical oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 38 | $484,355 |
| IbrancePalbociclib | 29 | $463,368 |
| OrserduElacestrant Hcl | 17 | $383,821 |
| ZejulaNiraparib Tosylate | 16 | $295,526 |
| EliquisApixaban | 13 | $10,445 |
| Exemestane | 55 | $5,200 |
| Anastrozole | 195 | $3,399 |
| Letrozole | 47 | $720 |
| Gabapentin | 38 | $404 |
| Dexamethasone | 31 | $313 |
| Potassium Chloride | 50 | $167 |
| Alendronate Sodium | 20 | $133 |
| Ondansetron Hcl | 25 | $119 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Sleepy Hollow
- Craig ThompsonNew York$4.8M
- Andrew SeidmanNew York$1.3M
- Maria TheodoulouAlbany$1.1M
- Joshua RichterNew York$971K
- Edward GelmannNew York$944K
- Anthony MatoIthaca$909K
- Ehsan MalekBuffalo$826K
- Ghassan Abou-AlfaNew York$825K
- Miguel PeralesNew York$769K
- Komal JhaveriNew York$642K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.